PTEN-KD led to early tumor progression with Tam treatment, suggesting that Tam may have acquired more estrogen agonist and less antagonist activity, similar to the effect we showed previously in a HER2-overexpressing xenograft model [49]. The gene discussed is ERBB2; the disease is neoplasm.